YILING PHARMACEUTICAL(SZ:002603)2025-10-29 09:06Group 1: Company Overview and Market Position - Yiling Pharmaceutical is recognized as the company with the most approved innovative traditional Chinese medicine (TCM) products since 2020 [2] - The company has established a comprehensive management system for intellectual property and trade secrets to protect its innovations [2] Group 2: Product Promotion Strategies - In the hospital market, the company is enhancing specialized promotion efforts based on five national key research projects [3] - In the external market, the company focuses on brand strategy, aiming to strengthen brand building and improve customer compliance with products [3] Group 3: Innovative Drug Development - The company has multiple innovative drugs in clinical stages, including XY0206 for acute myeloid leukemia and XY03-EA for ischemic stroke [6] - Future R&D plans include over ten products in respiratory, endocrine, digestive, gynecological, and pediatric fields [4] Group 4: Sales Expectations and Strategies - The BaZi Kidney Supplement Capsule is expected to enhance immune function and improve aging-related symptoms, with research published in high-impact journals [7][8] - The company is increasing sales efforts through retail and e-commerce channels, focusing on brand building and customer relationship management [8] Group 5: Market Potential and Financial Outlook - The market for diabetic retinopathy treatment is promising, with approximately 116.4 million diabetes patients in China and a DR prevalence rate of about 34.6% [11] - The company anticipates a recovery in gross profit margins due to declining prices of traditional Chinese medicinal materials and internal efficiency improvements [12]